2024-11-16 08:38:23
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2b Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction
Corporate/ 2023-07-24
Caliway Biopharmaceuticals Announces Ini...

- Caliway has initiated the subject recruitment in CBL-0204 Phase 2b study. - The study is expected to be completed in Q2 2024,and the topli...

Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 trials at the BIO International Convention
Corporate/ 2023-07-24
Actinogen to present progress on Cogniti...

Xanamem® is an oral,brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three p...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release